References
- BLOBE, G. C., SCHIEMANN, W. P. and LODISH, H. F. 2000, Role of transforming growth factor p in human diseases. New England Journal of Medicine, 342, 1350–1358.
- BORKOWSKI, T. A., LERREMO, J. J., FARR, A. G. and UDEY, M. C. 1996, A role for endogenous transforming growth factor beta 1 in Langerhans cell biology: the skin of transforming growth factor beta 1 null mice is devoid of epidermal Langerhans cells. Journal of Experimental Medicine, 184, 2417–2422.
- FLISIAK, R., PYREL-KROLCZUK, B. and PROKOPOWICZ, D. 2000, Circulating transforming growth factor pi as an indicator of hepatic function impairment in liver cirrhosis. Cytokine, 12, 677–681.
- FLISIAK, I., CHODYNICKA, B., PoRusiu, P. and FLISIAK, R 2002, Association between psoriasis severity and transforming growth factor 131 and 132 in plasma and scales from psoriatic lesions. Cytokine, 19, 121–125.
- FREDRLKSSON, T. and PERRERSSON, U. 1978, Severe psoriasis — oral therapy with a new retinoid. Dermatologica, 157, 238–244.
- FURUE, M., KATO, M., NAKAMURA, K., NASHIRO, K, KIKUCTIL, K, OKOCIII, H., MIYAZONO, K. and TAMAKI, K 1997, Dysregulated expression of transforming growth factor beta and its type-I and type-II receptors in basal-cell carcinoma. International Journal of Cancer, 71, 505–509.
- GOLD, L. I., JUSSILA, T., FUSENIG, N. E. and STENBACK, F 2000, TGF-beta isoforms are differentially expressed in increasing malignant grades of HaCaT keratinocytes, suggesting separate roles in skin carcinogenesis. Journal of Pathology, 190, 579–588.
- GRAINGER, D. J., MOSEDALE, D. E. and METCALFE, J. C. 2000, TGF-fl in blood: a complex problem. Cytokine and Growth Factor Review, 11, 133–145.
- KADUNCE, D. P. and KRUEGER, G. G. 1995, Pathogenesis of psoriasis. Dermatologic Clinics, 13, 723–737.
- KANE, C. J., KNAPP, A. M., MANSBRIDGE, J. N. and HANAWALT, P. C. 1990, Transforming growth factor-beta 1 localization in normal and psoriatic epidermal keratinocytes in situ. Journal of Cell Physiology, 144, 144–150.
- KAPP, A. 1993, The role of cytokines in the psoriatic inflammation. Journal of Dermatological Science, 5, 133–142.
- KONDO, S., HOZUMI, Y, MAEJIMA, H. and Aso, K 1992, Organ culture of psoriatic skin: effect of TGF-alpha and TGF-beta on epidermal structure in vitro. Archives of Dermatological Research, 284, 150–153.
- KRUEGER, J. G., KRANE, J. F, CARTER, D. M. and GOTTLIEB, A. B. 1990, Role of growth factors, cytokines, and their receptors in the pathogenesis of psoriasis. Journal of Investigative Dermatology, 94 (6 supplement), 135–140.
- LEIVO, T., LEIVO, I., KARINIEIVII, A. L, KESKI-OJA, J. and VIRTANEN, I. 1998, Down-regulation of transforming growth factor-beta receptors I and II is seen in lesional but not non-lesional psoriatic epidermis. British Journal of Dermatology, 138, 57–62.
- OYAMA, N., IWATSUKI, K., SATOH, M., AKIBA, H. and KANEKO, F. 2000, Dermal fibroblasts are one of the therapeutic targets for topical application of 1a,25-dihydroxyvitamin D3: the possible involvement of transforming growth factor-13 induction. British Journal of Dermatology, 143, 1140–1148.
- POWELL, T. J., BEN-BASSAT, H., KLEIN, B. Y., CHEN, H., SHENOY, N., MCCOILOUGH, J., NAROG, B., GAZIT, A., HARZSTARK, Z., CHAOUAT, M., LEVITZKL R, TANG, C., MCMAHON, J., SHAWVER, L. and LEVRRZIU, A. 1999, Growth inhibition of psoriatic keratinocytes by quinazoline tyrosine kinase inhibitors. British Journal of Dermatology, 141, 802–810.
- SINGER, A. J. and CI-ARK, R A. F. 1999, Cutaneous wound healing. New England Journal of Medicine, 341, 738–746.
- SUOMELA, S., KARINIEMI, A. L. and SNELLMAN, E. 2001, Metalloelastase (MMP-12) and 92-kDa gelatinase (M1vIP-9) as well as their inhibitors, TI1v1P-1 and -3, are expressed in psoriatic lesions. Experimental Dermatology, 10, 175–183.
- THOMPSON, M. and FEUTREN, G. 1997, Psoriasis Area and Severity Index. Basel: Novartis Pharma.
- WANG, X. J., GREENHALGH, D. A., BICKENBACH, J. R, JIANG, A., BLTNDMAN, D. S., KRIEG, T., DERYNCK, R. and Rom', D. R. 1997, Expression of a dominant-negative type II transforming growth factor beta (TGF-beta) receptor in the epidermis of transgenic mice blocks TGF-beta-mediated growth inhibition. Proceedings of the National Academy of Sciences of the USA, 94, 2386–2391.
- WATAYA-KANEDA, M., HASHIMOTO, K, KATO, M., MIYAZONO, K and YOSHIKAWA, K. 1996, Differential localization of TGF-beta-precursor isotypes in psoriatic human skin. Journal of Dermatological Science, 11, 183–188.
- WERNER, S., BEER, H. D., MAUCH, C., LUSCHER, B. and WERNER, S. 2001, The Madl transcription factor is a novel target of activin and TGF-beta action in keratinocytes: possible role of Madl in wound healing and psoriasis. Oncogene, 8, 7494–7504.